Tuesday, October 20, 2015

Johnson & Johnson's Stelara succeeds in Phase III Crohn's disease trial

(Reuters) - Johnson & Johnson's Stelara was significantly better than placebo at inducing clinical response and remissions in patients with moderate to severe Crohn's disease, according to data from a late stage trial, providing ammunition for a potential expanded approval of the medicine.

No comments:

Post a Comment